Timely Monitoring of Inflammation by Fecal Lactoferrin Rapidly Predicts Therapeutic Response in Inflammatory Bowel Disease

Simple item page
dc.contributor.authorSorrentino, Darioen
dc.contributor.authorGray, James M.en
dc.date.accessioned2022-10-11T13:26:06Zen
dc.date.available2022-10-11T13:26:06Zen
dc.date.issued2021-08en
dc.description.abstractBackground: Fecal lactoferrin (FL) levels may mirror drug-induced changes in inflammation in ulcerative colitis and Crohn disease in a timely way and could be used to assess loss of response (LOR) to biologics. Methods: This study is a retrospective outcome review in 61 patients on adalimumab, infliximab, or vedolizumab managed in our center and followed for 6 to 24 months. Patients were 1) in clinical remission or 2) were experiencing possible LOR. Results: For group 1, in 71% of 31 patients, FL slowly increased during the therapeutic interval (R-2=0.769; P<0.001), thus reflecting increasing inflammation as drug concentrations decreased. In the remaining patients, FL was undetectable throughout the therapeutic interval because of a stronger suppression of inflammation. For group 2, in 30 patients negative for infections, FL levels measured 1 to 3 days after infusion/injection compared to preadministration values either increased (nonresponders)-in these patients the medication was switched to another class; partially decreased (partial responders)-the therapeutic interval was shortened; or were normal throughout (responders)-causes for symptoms unrelated to disease activity were found for all. After FL-based management, 3-month standardized clinical scores were normalized in both partial responders (0.580.21 vs 0.13<plus/minus>0.09; P<0.001) and nonresponders (0.81<plus/minus>0.17 vs 0.12 +/- 0.08; P<0.001), and FL levels dropped by up to 99%. Conclusions: Levels of FL reflect drug-induced changes in mucosal inflammation in a timely way, thus enabling rapid assessment of therapeutic response in patients with ulcerative colitis and with Crohn disease. In patients with suspected LOR, FL levels before and after infusion/injection accurately separated responders, partial responders, and nonresponders. The strategy proposed here is simple, accurate, and easily applicable to clinical practice.en
dc.description.versionPublished versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.doihttps://doi.org/10.1093/ibd/izaa348en
dc.identifier.eissn1525-3163en
dc.identifier.issn0021-8812en
dc.identifier.issue9en
dc.identifier.urihttp://hdl.handle.net/10919/112130en
dc.identifier.volume100en
dc.language.isoenen
dc.publisherOxford University Pressen
dc.rightsCreative Commons Attribution-NonCommercial 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/en
dc.subjectinflammatory bowel diseasesen
dc.subjecttherapeutic responseen
dc.subjectfecal lactoferrinen
dc.titleTimely Monitoring of Inflammation by Fecal Lactoferrin Rapidly Predicts Therapeutic Response in Inflammatory Bowel Diseaseen
dc.title.serialJournal of Animal Scienceen
dc.typeArticle - Refereeden
dc.type.dcmitypeTexten

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
izaa348.pdf
Size:
1.34 MB
Format:
Adobe Portable Document Format
Description:
Published version
Download

Collections

Scholarly Works, Virginia Tech Carilion School of Medicine (VTCSOM)